Placebo News and Research

RSS

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Research presented at Digestive Disease Week explores new methods for managing digestive health through diet and lifestyle.

20 May 2013

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Shire plc, the global specialty biopharmaceutical company, announces that it will present scientific data in 7 poster presentations at the American Psychiatric Association 166th Annual Meeting in San Francisco, May 18-22.

20 May 2013

Non-invasive brain stimulation techniques improve memory

Non-invasive brain stimulation techniques aimed at mental and neurological conditions include transcranial magnetic stimulation for depression, and transcranial direct current (electrical) stimulation, shown to improve memory.

20 May 2013

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

UCB today announced data from a double-blind, placebo-controlled study that found that Neupro (Rotigotine Transdermal System) reduced total nocturnal systolic blood pressure elevations associated with periodic limb movements during sleep and total PLMS in patients with idiopathic moderate-to-severe Restless Legs Syndrome/Willis-Ekbom disease.

18 May 2013

Newer class of diabetes medications may also improve cardiovascular health, researchers report

A newer class of medications used to control blood sugar levels in type 2 diabetics may also improve cardiovascular health, researchers from The Ohio State University Wexner Medical Center reported in a new meta-analysis presented yesterday at the American Society of Hypertension's Annual Scientific Meeting and Exposition.

17 May 2013

UHCMC researchers to present data on patient and physician barriers to clinical trials

Researchers from University Hospitals Case Medical Center's Seidman Cancer Center will present findings from two studies evaluating new technologies designed to address common barriers to patient enrollment in clinical trials.

16 May 2013

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Bayer HealthCare announced today that new data on the oncology portfolio, including Nexavar (sorafenib) tablets, Stivarga (regorafenib) tablets and the recently U.S. Food and Drug Administration approved product Xofigo (radium Ra 223 dichloride) injection will be presented at the 49th Annual Meeting of the American Society of Clinical Oncology, May 31 – June 4, in Chicago, IL (USA).

16 May 2013

Simponi injection gets FDA approval to treat adults with ulcerative colitis

The U.S. Food and Drug Administration today approved a new use for Simponi (golimumab) injection to treat adults with moderate to severe ulcerative colitis.

16 May 2013

Prostate cancer drug Xofigo gets FDA approval

The U.S. Food and Drug Administration today approved Xofigo (radium Ra 223 dichloride) to treat men with symptomatic late-stage (metastatic) castration-resistant prostate cancer that has spread to bones but not to other organs.

16 May 2013

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

Bayer HealthCare announced today that patient enrollment is underway for RESORCE (Regorafenib after Sorafenib in Patients with Hepatocellular Carcinoma), an international Phase III trial to evaluate the efficacy and safety of Stivarga (regorafenib) tablets for the treatment of patients with hepatocellular carcinoma who have progressed on Nexavar (sorafenib) tablets, an anticancer medicine for the treatment of patients with unresectable HCC.

15 May 2013

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

The Government of India's Department of Biotechnology and Bharat Biotech announced positive results from a Phase III clinical trial of a rotavirus vaccine developed and manufactured in India.

14 May 2013

Clinical study reveals that Kava could be an alternative treatment for GAD

A world-first completed clinical study by an Australian team has found Kava, a medicinal South Pacific plant, significantly reduced the symptoms of people suffering anxiety.

14 May 2013

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

The University of New Mexico Cancer Center is among a few select institutions nationwide participating in a Phase 3 clinical trial studying a novel treatment for men with newly diagnosed, localized prostate cancer.

13 May 2013

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

The U.S. Food and Drug Administration today approved Breo Ellipta (fluticasone furoate and vilanterol inhalation powder) for the long-term, once-daily, maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease, including chronic bronchitis and/or emphysema.

13 May 2013

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Lexicon Pharmaceuticals, Inc. announced today that it is progressing into the placebo-controlled portion of its Phase 2 clinical trial of LX4211 in patients with type 1 diabetes, having successfully completed the open-label, pioneer portion of the trial.

10 May 2013

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients.

10 May 2013

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

Novartis announced that the US Food and Drug Administration has approved Ilaris (canakinumab) for the treatment of active systemic juvenile idiopathic arthritis in patients aged 2 years and older.

10 May 2013

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

InSite Vision Incorporated today announced that patient enrollment has begun in the confirmatory Phase 3 clinical trial of BromSite (ISV-303) for the reduction of inflammation and pain after cataract surgery.

10 May 2013

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Trevena, Inc., a clinical stage pharmaceutical company and the leader in the discovery and development of G-protein coupled receptor biased ligands, and Forest Laboratories Holding Limited, a subsidiary of Forest Laboratories Inc., an international pharmaceutical company, announced today that they have entered into a collaborative licensing option agreement for the development of TRV027, an AT1R biased-ligand that recently completed Phase 2a clinical trials.

9 May 2013

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Idera Pharmaceuticals today announced presentation of data from its randomized, double-blind, placebo-controlled Phase 2 trial that showed improvements from baseline of up to 90% in Psoriasis Area Severity Index scores in patients with moderate to severe plaque psoriasis following four weeks of treatment with the Toll-like Receptor antagonist IMO-3100.

8 May 2013

Placebo News and Research

Research highlights benefits of vitamin D, diet changes in patients with Crohn's disease

Shire's scientific data on treatments for psychiatric disorders to be presented at APA meeting

Non-invasive brain stimulation techniques improve memory

Neupro reduces PLMS and total NSBP elevations in patients with RLS, study finds

Newer class of diabetes medications may also improve cardiovascular health, researchers report

UHCMC researchers to present data on patient and physician barriers to clinical trials

Bayer HealthCare to present new data on oncology portfolio at ASCO meeting

Simponi injection gets FDA approval to treat adults with ulcerative colitis

Prostate cancer drug Xofigo gets FDA approval

Bayer HealthCare: Patient enrollment underway in Phase III trial of Stivarga tablets for treatment of HCC

India's DBT, Bharat Biotech announce positive Phase III clinical trial results of rotavirus vaccine

Clinical study reveals that Kava could be an alternative treatment for GAD

UNM Cancer Center to participate in Phase 3 clinical trial of novel treatment for men with prostate cancer

Breo Ellipta gets FDA approval for treatment of airflow obstruction in patients with COPD

Lexicon Pharmaceuticals advances Phase 2 clinical trial of LX4211 in patients with type 1 diabetes

Headline results of Creabilis' CT327 Phase 2b trial in psoriasis patients announced

FDA approves Novartis' Ilaris for treatment of active systemic juvenile idiopathic arthritis

InSite Vision starts patient enrollment in confirmatory Phase 3 clinical trial of BromSite

Trevena, Forest sign collaborative agreement to develop TRV027 for treatment of ADHF

Idera to present data from Phase 2 trial of IMO-3100 in patients with psoriasis at IID 2013

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News